Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)

被引：0
|
作者：
Wang, J. [1 ]
Cheng, Y. [2 ]
Wu, Y-L. [3 ]
An, T. [4 ]
Gao, H. [5 ]
Wang, K. [6 ]
Zhou, Q. [3 ]
Hu, Y. [7 ,13 ]
Song, Y. [8 ]
Ding, C. [9 ]
Ye, X. [10 ]
Peng, F. [11 ]
Liang, L. [12 ]
Hu, Y. [7 ,13 ]
Huang, C. [14 ]
Zhou, C. [15 ]
Shi, Y-K. [16 ]
Zhang, L. [17 ]
Gu, Y. [10 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Internal Med, Beijing, Peoples R China
[2] Jilin Prov Canc Hosp, Med Oncol, Changchun, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[4] Peking Univ, Canc Hosp, Beijing Canc Hosp, Thorac Med Oncol, Beijing, Peoples R China
[5] PLA AMMS China, Hosp 307, Med Oncol, Beijing, Peoples R China
[6] Zhejiang Canc Hosp, Genet, Hangzhou, Zhejiang, Peoples R China
[7] Hubei Prov Tumor Hosp, Med Oncol, Wuhan, Peoples R China
[8] Nanjing Mil Gen Hosp, Oncol, Nanjing, Jiangsu, Peoples R China
[9] Hebei Prov Tumor Hosp, Oncol, Shijiazhuang, Peoples R China
[10] AstraZeneca, Asia & Emerging Markets iMed, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[12] Beijing Univ, Hosp 3, Med Oncol, Beijing, Peoples R China
[13] Chinese Peoples Liberat Army Gen Hosp, Med Oncol, Beijing, Peoples R China
[14] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Peoples R China
[15] Tongji Univ, Tongji Hosp, Lung Canc Oncol & Immunol, Shanghai, Peoples R China
[16] Chinese Acad Med Sci, Canc Inst & Hosp, Med Oncol, Beijing, Peoples R China
[17] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.88
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1288TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
    Wang, J.
    Cheng, Y.
    Wu, Y.
    An, T.
    Gao, H.
    Wang, K.
    Zhou, Q.
    Hu, Y.
    Song, Y.
    Ding, C.
    Peng, F.
    Liang, L.
    Hu, Y.
    Huang, C.
    Zhou, C.
    Shi, Y.
    Zhang, L.
    Ye, X.
    Sun, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1844 - S1844
  • [2] Comparison of ddPCR and qPCR for detection of EGFR mutations in plasma cell-free DNA in Lung Adenocarcinoma.
    Uyboco, J.
    Aguilera, M. S.
    Andal, J. J.
    Dy, V.
    Cruz-Ordinario, M. V.
    Li, R.
    Ang, D.
    VIRCHOWS ARCHIV, 2019, 475 : S135 - S135
  • [3] Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as a first-line therapy
    Lee, Young Joo
    Yoon, Kyong-Ah
    Lee, Jin Soo
    CANCER RESEARCH, 2011, 71
  • [4] Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy
    Lee, Young Joo
    Yoon, Kyong-Ah
    Han, Ji-Youn
    Kim, Heung Tae
    Yun, Tak
    Lee, Geon Kook
    Kim, Hyae Young
    Lee, Jin Soo
    CLINICAL CANCER RESEARCH, 2011, 17 (15) : 5179 - 5187
  • [5] Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
    Douglas, R.
    Campbell, L.
    McAleese, J.
    Scullin, P.
    LUNG CANCER, 2013, 79 : S9 - S9
  • [6] Clinical feasibility of EGFR mutation detection by CastPCR in plasma cell-free DNA of lung adenocarcinoma patients
    Yang, Y.
    Hang, Z.
    Xiaoyan, S.
    Lixia, Y.
    Baorui, L.
    Lifeng, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma
    Cui, Shaohua
    Ye, Lin
    Wang, Huimin
    Chu, Tianqing
    Zhao, Yizhuo
    Gu, Aiqin
    Xiong, Liwen
    Shi, Chunlei
    Jiang, Liyan
    CLINICAL LUNG CANCER, 2018, 19 (03) : E313 - E322
  • [8] Combination of Chemotherapy and Gefitinib as First-Line Treatment of Patients with Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations
    Jin, Bo
    Niu, Yanjie
    Zhang, Yanwei
    Chu, Tianqing
    Gu, Aiqin
    Pei, Jun
    Han, Baohui
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S646
  • [9] Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomised controlled trial
    Han, B.
    Jin, B.
    Zhang, Y.
    Chu, T.
    Gu, A.
    Xu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S113 - S114
  • [10] Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
    Han, Baohui
    Jin, Bo
    Chu, Tianqing
    Niu, Yanjie
    Dong, Yu
    Xu, Jianlin
    Gu, Aiqing
    Zhong, Hua
    Wang, Huimin
    Zhang, Xueyan
    Shi, Chunlei
    Zhang, Yanwei
    Zhang, Wei
    Lou, Yuqing
    Zhu, Lei
    Pei, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (06) : 1249 - 1256
12345